Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity

No Thumbnail Available
File version
Author(s)
Amin, M
Mays, MA
Polston, D
Flanagan, EP
Prayson, R
Kunchok, A
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
License
Abstract

We present a patient with positive medium titer MOG-IgG and progressive neurological decline whose clinical and radiological phenotype were not consistent with a MOG-IgG associated disorder and ultimately received a diagnosis of glioblastoma after brain biopsy and died 4 weeks later. This represents an important topic with a high frequency of MOG-IgG testing in clinical practice. Due to this there are increasing reports of MOG-IgG positivity in atypical clinical phenotypes, raising the possibility of false positives, which can have important implications. It is important to highlight that judicious clinical evaluation is needed when interpreting MOG-IgG results in atypical settings.

Journal Title
Journal of Neuroimmunology
Conference Title
Book Title
Edition
Volume
361
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Immunology
Neurosciences
Antibody
False positive
Glioblastoma
MOG
Persistent link to this record
Citation
Amin, M; Mays, MA; Polston, D; Flanagan, EP; Prayson, R; Kunchok, A, Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity, Journal of Neuroimmunology, 2021, 361, pp. 577743
Collections